Data / Form D filings / Apnimed, Inc.
Apnimed, Inc.: Form D filings
Apnimed, Inc., a pharmaceuticals company in Cambridge, MA, filed 15 Form D notices with the SEC between 2018 and 2026. The latest, on March 27, 2026, reports $25 million sold of a $25 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 39 JOHN F. KENNEDY STREET, 4TH FLR., Cambridge, MA, 02138
- Phone
- (877) 276-4633
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1745648
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | New notice | $24,999,994 | $24,999,994 | 2 | Mar 11, 2026 | sec.gov | |
| Dec 8, 2025 | Amendment | $35,000,000 | $35,000,000 | 7 | Sep 17, 2025 | sec.gov | |
| Oct 1, 2025 | Amendment | $35,000,000 | $35,000,000 | 7 | Sep 17, 2025 | sec.gov | |
| Sep 24, 2025 | New notice | $23,000,000 | $23,000,000 | 7 | Sep 17, 2025 | sec.gov | |
| Apr 24, 2025 | New notice | $16,499,982 | $16,499,982 | 3 | Apr 23, 2025 | sec.gov | |
| Nov 8, 2023 | New notice | $37,499,980 | $0 | $37,499,980 | 1 | Nov 1, 2023 | sec.gov |
| Dec 23, 2022 | New notice | $79,749,950 | $79,749,950 | 6 | Dec 22, 2022 | sec.gov | |
| Nov 1, 2022 | Amendment | $62,499,913 | $62,499,913 | 14 | Apr 28, 2022 | sec.gov | |
| May 10, 2022 | New notice | $62,499,913 | $37,499,995 | $24,999,918 | 14 | Apr 28, 2022 | sec.gov |
| Mar 25, 2021 | New notice | $24,999,982 | $24,999,982 | 3 | Mar 12, 2021 | sec.gov | |
| Apr 7, 2020 | New notice | $15,000,000 | $15,000,000 | 1 | Mar 31, 2020 | sec.gov | |
| Aug 7, 2019 | Amendment | $25,575,714 | $25,575,714 | 12 | Jun 25, 2018 | sec.gov | |
| Jan 10, 2019 | Amendment | $25,575,714 | $19,575,714 | $6,000,000 | 12 | Jun 25, 2018 | sec.gov |
| Aug 9, 2018 | Amendment | $25,575,714 | $9,575,714 | $16,000,000 | 12 | Jun 25, 2018 | sec.gov |
| Jul 6, 2018 | New notice | $25,575,714 | $5,075,713 | $20,500,001 | 12 | Jun 25, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Lawrence G. Miller | Executive Officer, Director | |
| Barry Wohl | Executive Officer | |
| Dennis Molnar | Executive Officer | |
| Joseph C. Avellone | Director | |
| Francois Beaubien | Director | |
| Isaac Cheng | Director | |
| Chris C. Dimitropoulos | Director | |
| Paul Fonteyne | Director | |
| Kevin C. Lind | Director | |
| Gary Sender | Director | |
| Ramzi Benamar | Executive Officer |
Other pharmaceuticals companies in Massachusetts that filed recently
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Mar 23, 2026 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Apnimed, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.